Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Madhup Rastogi is active.

Publication


Featured researches published by Madhup Rastogi.


Journal of Cancer Research and Therapeutics | 2010

Concurrent chemoradiation in locally advanced carcinoma cervix patients.

Rr Negi; Manish Gupta; Muninder Kumar; Meenu Gupta; Rajeev Kumar Seam; Madhup Rastogi

PURPOSE To investigate the feasibility of concurrent chemo radiation in locally advanced carcinoma cervix patients in our clinical setting. MATERIALS AND METHODS From Sept. 1st 2005 to Aug. 31st 2006, 102 patients of carcinoma cervix belonging to stage IIA to IV A were enrolled in the study. External beam radiation therapy was administered using Cobalt 60 teletherapy machine. Cisplatinum (40 mg/m 2) and 5 Fluorouracil (500 mg/m 2 ) continuous infusions with radiotherapy on D2-D5 in first and last 5 # of radiation therapy were administered. RESULTS Response to treatment and toxicities were monitored and analyzed in 102 patients (50 study group and 52 control group). All 102 patients completed treatment. Out of 50 patients in the study group, 30, 10 and 4 patients had complete, partial and progressive disease, respectively. While out of 52 patients in the control group, 26 had complete and 12 showed partial response. No difference in overall renal, hematological and cutaneous toxicity was seen between two groups. CONCLUSION This study did not show any benefit of concurrent chemo radiation as compared to radiotherapy alone in locally advanced cervical cancer patients. This could be due to more bulk of tumor stage per stage, poor nutritional status, less number of patients in both arms, not enough to pick up statistically significant small difference in outcome.


European Journal of Cancer Care | 2011

Oral mucositis in head and neck cancer.

Madhup Rastogi; Raghav C. Dwivedi; R. Kazi

This module explores the risk factors, pathogenesis and development of oral mucositis. It considers the early diagnosis and accurate management of oral mucositis in head and cancer patients undergoing treatment.


Case Reports | 2012

Paraneoplastic Raynaud's phenomenon manifesting before the diagnosis of lung cancer

Irappa Madabhavi; Swaroop Revannasiddaiah; Madhup Rastogi; Manoj Kumar Gupta

This description pertains to a previously healthy gentleman aged 54 years who developed symptoms coherent with Raynaud’s phenomenon. The patient never had any prior episodes of peripheral cyanosis. The patient’s first presentation was in summer and the paroxysms of peripheral cyanosis were not associated with any specific aggravating factor. The paroxysms went on to become more severe and painful across a span of 6 months, when he also developed non-radiating pain in the right lateral chest-wall, which would aggravate after episodes of cough. A chest roentgenogram then demonstrated the presence of a mass lesion in the right lung and a fine-needle-aspiration cytology confirmed malignancy- an adenocarcinoma. There was a dramatic relief in pain and a reduction in the intensity and duration of paroxysms of peripheral cyanosis within 2-weeks of initiation of chemotherapy for lung cancer.


Annals of Translational Medicine | 2015

The results with the addition of metronomic cyclophosphamide to palliative radiotherapy for the treatment of non-small cell lung carcinoma

Swaroop Revannasiddaiah; Subhash Chandra Joshi; Kailash Chandra Pandey; Madhup Rastogi; Mukesh Sharma; Manoj Kumar Gupta

BACKGROUND A considerable proportion of non-small cell lung carcinoma (NSCLC) patients are ineligible for radical therapies. Many are frail not to tolerate intravenous palliative chemotherapy either. These patients often receive palliative radiotherapy (RT), or supportive care alone. We intend to compare outcomes with palliative RT alone, versus palliative RT plus oral low dose metronomic cyclophosphamide. METHODS Data was mined from 139 eligible NSCLC patient records. Comparisons were made between 65 patients treated from January 2011 to March 2013 with palliative RT (20-30 Gray in 5-10 fractions) alone, versus 74 patients treated from April 2013 to December 2014 with palliative RT plus oral metronomic cyclophosphamide (50 mg once daily from day of initiation of RT until at least the day of disease progression). Response was assessed after 1-month post-RT by computed tomography. Patients with complete or partial response were recorded as responders. For the determination of progression free survival (PFS), progression would be declared in case of increase in size of lesions, development of new lesions, or development of effusions. The proportions of responders were compared with the Fisher exact test, and the PFS curves were compared with the log-rank test. RESULTS Differences in response rates were statistically insignificant. The PFS was significantly higher when metronomic chemotherapy was added to RT in comparison to treatment with RT alone (mean PFS 3.1 vs. 2.55 months; P=0.0501). Further histological sub-group analysis revealed that the enhanced outcomes with addition of metronomic cyclophosphamide to RT were limited to patients with adenocarcinoma histology (3.5 vs. 2.4 months; P=0.0053), while there was no benefit for those with squamous cell histology (2.6 vs. 2.6 months; P=1). At the dose of oral cyclophosphamide used, there was no recorded instance of any measurable hematological toxicity. CONCLUSIONS For pulmonary adenocarcinoma patients, the treatment with palliative RT plus oral metronomic cyclophosphamide is better than that with palliative RT alone. However, for pulmonary squamous cell carcinoma the addition of oral metronomic cyclophosphamide to palliative RT offered no benefit. Further studies with similar and different metronomic chemotherapy agents are justifiable.


Indian Journal of Palliative Care | 2013

Palliative radiotherapy in locally advanced head and neck cancer after failure of induction chemotherapy: Comparison of two fractionation schemes

Kailash Chandra Pandey; Swaroop Revannasiddaiah; Nirdosh Kumar Pant; Vipul Nautiyal; Madhup Rastogi; Manoj Kumar Gupta

Context: Among patients with locally advanced head and neck squamous cell cancers (LAHNSCC), the prognosis after nonresponse or progression despite induction chemotherapy (IC) is dismal, and further treatment is often palliative in intent. Given that nonresponse to chemotherapy could indicate subsequent radioresistance, we intended to assess the outcomes with two different fractionation schemes. Aims: To compare the outcomes of two fractionation schemes- ’standard’ (consisting 3GyX5 daily fractions for 2 consecutive weeks) versus ‘hybrid’ (6GyX3 fractions on alternate days during the 1st week, followed by 2GyX5 daily fractions in the 2nd week). Settings and Design: Prospective randomized controlled two-arm unblinded trial. Materials and Methods: Patients with locally advanced oropharyngeal, laryngeal, and hypopharyngeal cancers treated with a minimum of two cycles of taxane, platinum, and fluorouracil-based IC were eligible if residual disease volume amounted <30 cm3. Kaplan-Meier survival curves were compared by the log-rank test. Response rates were compared using the unpaired t-test. Quality of life (QOL) was measured via patient reported questionnaires. Results: Of the initially enrolled 51 patients, 45 patients (24 from standard arm, and 21 from the hybrid arm) were eligible for analysis. Despite being underpowered to attain statistical significance, there still seemed to be a trend towards improvement in progression-free (Hazard ratio (HR) for progression: 0.5966; 95% CI 0.3216-1.1066) and overall survival (HR for death: 0.6062; 95% CI 0.2676-1.3734) with the hybrid arm when compared to the standard arm. Benefits were also observed with regards to response rates and QOL. Rate of complications were similar in both arms. Conclusions: In comparison to the routinely used palliative fractionation scheme of 30 Gray (Gy) in 10 fractions (Fr), the use of hybrid fractionation which integrates hypofractionation in the 1st week, followed by conventional fractionation in the 2nd week, could possibly offer better response rates, QOL increments, and potential survival benefits among LAHNSCC patients even after failing to respond to IC.


Asian Pacific Journal of Cancer Prevention | 2016

Peripheral Blood Lymphocytes as In Vitro Model to Evaluate Genomic Instability Caused by Low Dose Radiation.

Shikha Tewari; Kainat Khan; Nuzhat Husain; Madhup Rastogi; Surendra P Mishra; Anoop K Srivastav

Diagnostic and therapeutic radiation fields are planned so as to reduce side-effects while maximising the dose to site but effects on healthy tissues are inevitable. Radiation causes strand breaks in DNA of exposed cells which can lead to chromosomal aberrations and cause malfunction and cell death. Several researchers have highlighted the damaging effects of high dose radiation but still there is a lacuna in identifying damage due to low dose radiation used for diagnostic purposes. Blood is an easy resource to study genotoxicity and to estimate the effects of radiation. The micronucleus assay and chromosomal aberration can indicate genetic damage and our present aim was to establish these with lymphocytes in an in vitro model to predict the immediate effects low dose radiation. Blood was collected from healthy individuals and divided into 6 groups with increasing radiation dose i.e., 0Gy, 0.10Gy, 0.25Gy, 0.50Gy, 1Gy and 2Gy. The samples were irradiated in duplicates using a LINAC in the radiation oncology department. Standard protocols were applied for chromosomal aberration and micronucleus assays. Metaphases were stained in Giemsa and 200 were scored per sample for the detection of dicentric or acentric forms. For micronuclei detection, 200 metaphases. Giemsa stained binucleate cells per sample were analysed for any abnormality. The micronuclei (MN) frequency was increased in cells exposed to the entire range of doses (0.1- 2Gy) delivered. Controls showed minimal MN formation (2.0%±0.05) with triple MN (5.6%±2.0) frequency at the lowest dose. MN formation increased exponentially with the radiation dose thereafter with a maximum at 2Gy. Significantly elevated numbers of dicentric chromosomes were also observed, even at doses of 0.1- 0.5Gy, compared to controls, and acentric chromosomes were apparent at 2Gy. In conclusion we can state that lymphocytes can be effectively used to study direct effect of low dose radiation.


Journal of Cancer Research and Therapeutics | 2014

Triple primary malignant neoplasms including breast, esophagus and base tongue in an elderly male: A case report

Madhup Rastogi; Sudhir Singh; Sameer Gupta; Raghav C. Dwivedi

Cases involving more than two primary malignant neoplasms are very rare. The present article reports a case of multiple primary malignant neoplasms including esophagus initially followed by right breast and later base of tongue in an elderly male patient, which is extremely a rare combination.


Chinese Journal of Cancer | 2013

Müllerian duct anomalies and their effect on the radiotherapeutic management of cervical cancer.

Madhup Rastogi; Swaroop Revannasiddaiah; Pragyat Thakur; Priyanka Thakur; Manish Gupta; Manoj Kumar Gupta; Rajeev Kumar Seam

Radiotherapy plays a major role in the treatment of cervical cancer. A successful radiotherapy program integrates both external beam and brachytherapy components. The principles of radiotherapy are strongly based on the anatomy of the organ and patterns of local and nodal spread. However, in patients with distorted anatomy, several practical issues arise in the delivery of optimal radiotherapy, especially with brachytherapy. Müllerian duct anomalies result in congenital malformations of the female genital tract. Though being very commonly studied for their deleterious effects on fertility and pregnancy, they have not been recognized for their potential to interfere with the delivery of radiotherapy among patients with cervical cancer. Here, we discuss the management of cervical cancer among patients with Müllerian duct anomalies and review the very sparse amount of published literature on this topic.


Indian Journal of Palliative Care | 2012

When Palliative Treatment Achieves More Than Palliation: Instances of Long-term Survival after Palliative Radiotherapy.

Madhup Rastogi; Swaroop Revannasiddaiah; Manoj Kumar Gupta; Rajeev Kumar Seam; Priyanka Thakur; Manish Gupta

Context: Palliative radiotherapy aims at symptom alleviation and improvement of quality of life. It may be effective in conferring a reasonable quantum of local control, as well as possibly prolonging survival on the short term. However, there can be rare instances where long-term survival, or even cure, results from palliative radiotherapy, which mostly uses sub-therapeutic doses. Aim: To categorize and characterize the patients with long-term survival and/or cure after palliative radiotherapy. Materials and Methods: This study is a retrospective analysis of hospital records of patients treated with palliative radiotherapy from 2001 to 2006 at the Regional Cancer Centre, Shimla. Results: Of the analyzed 963 patients who received palliative radiotherapy, 2.4% (n = 23) survived at least 5 years, with a large majority of these surviving patients (73.9%, n = 17) being free of disease. Conclusions: In addition to providing valuable symptom relief, palliative radiotherapy utilizing sub-therapeutic doses may, in a small proportion of patients, bestow long-term survival, and possibly cure. Rationally, such a favorable, but rare outcome cannot be expected with supportive care alone.


Case Reports | 2012

Dermatomyositis and chest radiography leading to the diagnosis of lung cancer and subsequent confusions in staging due to the presence of tuberculosis

Swaroop Revannasiddaiah; Manoj Kumar Gupta; Madhup Rastogi; Avinash Arjun Rao Kesari; Rajeev Kumar Seam; Manish Gupta; Suneel Chauhan; Irappa Madabhavi

This clinical scenario describes dermatomyositis as a presenting feature of carcinoma of the lung. However, the coincident existence of tuberculosis in the opposite lung gave rise to a false impression of contralateral lung metastasis and hence confusions with regard to staging ensued, which were clarified after further investigation confirmed a unilateral lung adenocarcinoma and contralateral tuberculosis. The patient was initiated on oral antiepidermal growth factor receptor therapy with erlotinib, as well as on multi-drug therapy for tuberculosis. This report intends to illustrate that paraneoplastic syndromes such as dermatomyositis can be the presenting feature of lung cancer, and also that the co-incident presence of carcinoma and tuberculosis can cause confusions with regard to staging and management.

Collaboration


Dive into the Madhup Rastogi's collaboration.

Top Co-Authors

Avatar

Manoj Kumar Gupta

Nanyang Technological University

View shared research outputs
Top Co-Authors

Avatar

Rajeev Kumar Seam

Indira Gandhi Medical College

View shared research outputs
Top Co-Authors

Avatar

Priyanka Thakur

Indira Gandhi Medical College

View shared research outputs
Top Co-Authors

Avatar

M.L.B. Bhatt

King George's Medical University

View shared research outputs
Top Co-Authors

Avatar

Madhu Srivastava

King George's Medical University

View shared research outputs
Top Co-Authors

Avatar

Manish Gupta

Indira Gandhi Medical College

View shared research outputs
Top Co-Authors

Avatar

Ajeet Kumar Gandhi

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Kirti Srivastava

King George's Medical University

View shared research outputs
Top Co-Authors

Avatar

Mohan C. Pant

King George's Medical University

View shared research outputs
Top Co-Authors

Avatar

Mukesh Sharma

Indira Gandhi Medical College

View shared research outputs
Researchain Logo
Decentralizing Knowledge